Literature DB >> 22537442

Will interferon-free regimens prevail?

Christoph Welsch1, Stefan Zeuzem.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22537442     DOI： 10.1053/j.gastro.2011.12.062

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  3 in total

1.  Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Authors:  Jeff A O'Meara; Christopher T Lemke; Cédrickx Godbout; George Kukolj; Lisette Lagacé; Benoît Moreau; Diane Thibeault; Peter W White; Montse Llinàs-Brunet
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

Review 2.  Future therapies for chronic hepatitis C.

Authors:  Noura M Dabbouseh; Donald M Jensen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

3.  Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.

Authors:  Wei-Lun Tsai; Chih-Feng Wang; Jin-Shiung Cheng; Wen-Chi Chen; Ming-Jong Bair; Ching-Chu Lo
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.